| Suspended | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing He NCT06968195 | Roswell Park Cancer Institute | Phase 1 |
| Not Yet Recruiting | Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Loca NCT07511504 | OHSU Knight Cancer Institute | Phase 2 |
| Not Yet Recruiting | Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer NCT07042919 | Northwestern University | Phase 1 / Phase 2 |
| Recruiting | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Canc NCT07166406 | NRG Oncology | Phase 3 |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer NCT07174570 | Emory University | Phase 2 |
| Recruiting | Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) NCT06811116 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease NCT05791448 | University of Southern California | Phase 1 |
| Terminated | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezoliz NCT05199285 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, NCT05168163 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant NCT05103904 | Emory University | Phase 2 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Recruiting | Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcino NCT04430452 | Mary Feng, MD | Phase 2 |
| Completed | 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer NCT05176223 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver NCT04605731 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events NCT05038254 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer NCT04380545 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers NCT04221893 | University of California, San Francisco | N/A |
| Active Not Recruiting | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver NCT04175912 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) NCT03896646 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inh NCT03942328 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Adv NCT04022746 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Intravital Microscopy in Human Solid Tumors NCT03823144 | Mayo Clinic | N/A |
| Active Not Recruiting | IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver NCT03655002 | City of Hope Medical Center | Phase 1 |
| Terminated | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer NCT03695250 | Edward Kim | Phase 1 / Phase 2 |
| Completed | Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cance NCT03439891 | Robin Kate Kelley | Phase 2 |
| Completed | Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma NCT01176604 | M.D. Anderson Cancer Center | N/A |